We’re in Munich 🇩🇪 with the founder of one of the 15 most valuable European biotechs, Harpreet Singh. We talked about the field of PRAME receptors, TCR therapeutics and cell therapy at large. We also talked about the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany. 🔗 LINKS MENTIONED Labiotech.eu | “Interview Harpreet Singh - Why Being in a New Field From the Start Can Pay Off in the Long Run”, Sep 2019: https://www.labiotech.eu/expert-advice/interview-singh-immatics/ Flot.bio | “Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14”, Mar 2024: https://www.youtube.com/watch?v=8bmGke4sRvE Edwin Moses | How to Build Large Biotech Platforms (like Ablynx) | E13: https://youtu.be/oMBcFC3PqyM?si=xTcZF27F0UFjyQhb ApexOnco | Immatics’ PRAME gift keeps on giving: https://www.oncologypipeline.com/apexonco/immatics-prame-gift-keeps-giving 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/harpreet-singh-immatics/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:00] PRAME & TCR space [00:12:43] Types of Cell Therapy [00:25:44] Commercialization [00:29:11] Valuations in Gene Therapy [00:33:17] Fundraising with Dievini and Struengmann [00:43:46] Sikh origin [00:48:31] Expanding to the US [00:53:59] PhD to CEO [00:59:21] Quickfire [01:03:01] Thanks for listening